Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
Adult
Anti-Retroviral Agents
/ therapeutic use
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cohort Studies
Female
HIV Infections
/ immunology
HIV-1
/ immunology
Humans
Lymphocyte Activation
Male
Middle Aged
Viral Load
/ physiology
Viral Tropism
/ genetics
Viremia
/ immunology
Virus Replication
/ drug effects
HIV-1 control
HIV-1 progression
cell tropism
host genetics
in vitro virus inhibition
loss of control
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
15 02 2019
15 02 2019
Historique:
received:
21
08
2018
accepted:
16
11
2018
pubmed:
30
11
2018
medline:
7
1
2020
entrez:
30
11
2018
Statut:
epublish
Résumé
Elite and viremic HIV controllers are able to control their HIV infection and maintain undetectable or low-level viremia in the absence of antiretroviral treatment. Despite extensive studies, the immune factors responsible for such exclusive control remain poorly defined. We identified a cohort of 14 HIV controllers that suffered an abrupt loss of HIV control (LoC) to investigate possible mechanisms and virological and immunological events related to the sudden loss of control. The in-depth analysis of these subjects involved the study of cell tropism of circulating virus, evidence for HIV superinfection, cellular immune responses to HIV, as well as an examination of viral adaptation to host immunity by Gag sequencing. Our data demonstrate that a poor capacity of T cells to mediate
Identifiants
pubmed: 30487276
pii: JVI.01436-18
doi: 10.1128/JVI.01436-18
pmc: PMC6363998
pii:
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : G0502048
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : P01 AI131568
Pays : United States
Informations de copyright
Copyright © 2019 Rosás-Umbert et al.
Références
Nat Med. 1999 Nov;5(11):1233-5
pubmed: 10545982
J Clin Virol. 2010 Apr;47(4):376-8
pubmed: 20153976
J Virol. 1993 Apr;67(4):1772-7
pubmed: 8095306
BMC Med. 2018 Feb 28;16(1):30
pubmed: 29490663
J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):140-8
pubmed: 16186730
Immunity. 2012 Sep 21;37(3):426-40
pubmed: 22999948
J Immunol. 2004 May 15;172(10):6407-17
pubmed: 15128832
Science. 2007 Aug 17;317(5840):944-7
pubmed: 17641165
Nat Immunol. 2016 Aug;17(8):966-75
pubmed: 27270402
J Infect Dis. 2009 Dec 1;200(11):1714-23
pubmed: 19852669
PLoS Genet. 2009 Dec;5(12):e1000791
pubmed: 20041166
Nat Med. 2005 Jun;11(6):615-22
pubmed: 15880120
Retrovirology. 2012 Nov 06;9:91
pubmed: 23131037
J Infect Dis. 2008 Jan 1;197(1):126-33
pubmed: 18171295
J Virol. 2015 Aug;89(15):7521-35
pubmed: 25972547
J Virol. 2018 Feb 12;92(5):
pubmed: 29212942
J Clin Invest. 2018 Aug 31;128(9):4074-4085
pubmed: 30024859
AIDS. 1994 Aug;8(8):1123-8
pubmed: 7986410
J Infect Dis. 2008 Feb 15;197(4):563-71
pubmed: 18275276
PLoS One. 2009 Aug 19;4(8):e6687
pubmed: 19690614
J Infect Dis. 2018 Nov 5;218(12):1954-1963
pubmed: 30085241
J Acquir Immune Defic Syndr. 2007 May 1;45(1):28-33
pubmed: 17310935
Blood. 2004 Aug 15;104(4):942-7
pubmed: 15117761
J Virol. 2010 Dec;84(24):12971-81
pubmed: 20926564
Annu Rev Med. 2003;54:535-51
pubmed: 12525683
Dis Markers. 2009;27(3):105-20
pubmed: 19893207
J Virol. 2004 Mar;78(5):2187-200
pubmed: 14963115
J Virol. 2011 Sep;85(18):9334-45
pubmed: 21752903
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14
pubmed: 10694578
Curr Med Chem. 2011;18(26):3963-70
pubmed: 21824095
Mol Biol Evol. 1987 Jul;4(4):406-25
pubmed: 3447015
PLoS One. 2015 Jul 06;10(7):e0131922
pubmed: 26146823
J Virol. 2005 Jul;79(14):9006-18
pubmed: 15994794
AIDS. 2015 Nov;29(17):2245-54
pubmed: 26544698
Clin Infect Dis. 2008 Dec 1;47(11):e86-9
pubmed: 18947331
J Antimicrob Chemother. 2013 Jun;68(6):1382-7
pubmed: 23354282
Immunity. 2007 Sep;27(3):406-16
pubmed: 17892849
J Virol. 2007 Aug;81(16):8838-42
pubmed: 17537849
AIDS. 2016 May 15;30(8):1209-20
pubmed: 26854807
Nat Med. 2011 Jul 17;17(8):989-95
pubmed: 21765403
Mol Biol Evol. 2011 Oct;28(10):2731-9
pubmed: 21546353
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
Clin Immunol. 2011 Oct;141(1):15-30
pubmed: 21865089
AIDS. 2016 Jan 28;30(3):343-53
pubmed: 26588174
J Exp Med. 2008 Aug 4;205(8):1789-96
pubmed: 18625749
Nucleic Acids Res. 2015 Jan;43(Database issue):D784-8
pubmed: 25414323
AIDS. 2014 Sep 24;28(15):2323-5
pubmed: 25313587
PLoS One. 2017 Jan 27;12(1):e0166613
pubmed: 28129343
J Virol. 2006 Mar;80(6):3122-5
pubmed: 16501126
J Virol. 2016 Jul 11;90(15):6818-6831
pubmed: 27194762
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5393-400
pubmed: 25453107
EBioMedicine. 2014 Dec 22;2(1):46-58
pubmed: 26137533
J Immunol. 2009 Jun 15;182(12):7828-37
pubmed: 19494307
EBioMedicine. 2017 Feb;16:141-149
pubmed: 28159573
Retrovirology. 2018 Jan 16;15(1):7
pubmed: 29338738
Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a007443
pubmed: 23143844
JAMA. 2004 Sep 8;292(10):1177-8
pubmed: 15353529
Nature. 2002 Nov 28;420(6914):434-9
pubmed: 12459786
Lancet HIV. 2014 Oct;1(1):e41-8
pubmed: 26423816
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81
pubmed: 17428922
PLoS One. 2012;7(1):e29717
pubmed: 22238642
Evolution. 1985 Jul;39(4):783-791
pubmed: 28561359
Mol Biol Evol. 1993 May;10(3):512-26
pubmed: 8336541
J Virol. 2018 May 29;92(12):
pubmed: 29593044
J Virol. 2014 Sep 1;88(17):9789-98
pubmed: 24942573
AIDS Res Ther. 2017 Mar 20;14:15
pubmed: 28331526
J Virol. 2008 Jun;82(11):5398-407
pubmed: 18353945
J Immunol Methods. 2013 May 31;391(1-2):174-8
pubmed: 23500782
J Infect Dis. 2012 Aug 15;206(4):552-61
pubmed: 22711904
PLoS Pathog. 2015 Mar 17;11(3):e1004725
pubmed: 25781895